{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=45", "query": { "intervention": "Part 3", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 4019, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T06:29:14.717Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05083481", "title": "A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1570", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Trifluridine + Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2021-10-19", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 12, "location_summary": "Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05083481" }, { "nct_id": "NCT03916419", "title": "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIB Non-Small Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "ViewRay MR-Linear Accelerator", "type": "DEVICE" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin AUC", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DEVICE", "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-06-20", "completion_date": "2025-09-28", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03916419" }, { "nct_id": "NCT04067336", "title": "First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "Acute Myeloid Leukemia", "Mixed Lineage Leukemia", "Mixed Lineage Acute Leukemia", "Acute Leukemia of Ambiguous Lineage", "Mixed Phenotype Acute Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 263, "start_date": "2019-09-12", "completion_date": "2028-10-16", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04067336" }, { "nct_id": "NCT05438407", "title": "Pediatric Patients Aged 4 to 11 Years With APDS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "APDS" ], "interventions": [ { "name": "Leniolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharming Technologies B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Years to 11 Years" }, "enrollment_count": 15, "start_date": "2023-02-01", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 4, "location_summary": "Los Angeles, California • Standford, California • Atlanta, Georgia + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Standford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05438407" }, { "nct_id": "NCT04292899", "title": "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Remdesivir", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4891, "start_date": "2020-03-06", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 106, "location_summary": "Anaheim, California • Berkeley, California • Burlingame, California + 76 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04292899" }, { "nct_id": "NCT03541174", "title": "A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Resistant Hypertension" ], "interventions": [ { "name": "Aprocitentan 12.5 mg", "type": "DRUG" }, { "name": "Aprocitentan 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2018-06-18", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 41, "location_summary": "Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Inglewood", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541174" }, { "nct_id": "NCT06950190", "title": "Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-related Cognitive Impairment" ], "interventions": [ { "name": "Low-Intensity Walking Intervention", "type": "BEHAVIORAL" }, { "name": "Control Group Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Ellis Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-06-09", "completion_date": "2027-02-20", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 1, "location_summary": "Schenectady, New York", "locations": [ { "city": "Schenectady", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06950190" }, { "nct_id": "NCT02722668", "title": "UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia/Lymphoma", "Burkitt's Lymphoma", "Natural Killer Cell Malignancies", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Large-cell Lymphoma", "Hodgkin Lymphoma", "Multiple Myeloma", "Relapsed Chronic Lymphocytic Leukemia", "Relapsed Small Lymphocytic Lymphoma", "Marginal Zone B-cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-cell Lymphoma", "Prolymphocytic Leukemia", "Bone Marrow Failure Syndromes", "Myeloproliferative Neoplasms/Myelofibrosis", "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias", "MRD Positive Leukemia", "Leukemia or MDS in Aplasia", "Relapsed T-Cell Lymphoma", "Relapsed Multiple Myeloma", "Plasma Cell Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "TBI", "type": "RADIATION" }, { "name": "Umbilical cord blood cell infusion", "type": "BIOLOGICAL" }, { "name": "ATG", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 15, "start_date": "2017-05-15", "completion_date": "2024-02-22", "has_results": true, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722668" }, { "nct_id": "NCT03398720", "title": "Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "HTI-1066 dose level 1", "type": "DRUG" }, { "name": "HTI-1066 dose level 2", "type": "DRUG" }, { "name": "HTI-1066 dose level 3", "type": "DRUG" }, { "name": "HTI-1066 dose level 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2017-12-31", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2018-01-12", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03398720" }, { "nct_id": "NCT06115642", "title": "A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "HLX43", "type": "DRUG" }, { "name": "HLX10", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 367, "start_date": "2023-11-24", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-12T06:29:14.717Z", "location_count": 6, "location_summary": "Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06115642" } ] }